Sequenom (SQNM) - where do we go from here?

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Sequenom (SQNM) - where do we go from here?

An SI Board Since April 2014

Posts	SubjectMarks	Bans	Symbol
2	1	0	SQNM

Emcee: dr_elis	Type: Moderated

Introduction Market Data Compact

Among other things SQNM is a leader in Non-Invasive Prenatal Testing (NIPT)/Non-Invasive Prenatal Screening (NIPS). NIPS generated 2013 revenues of $ 200 million in the US. The global market opportunity is expected to grow to over $ 5 billion by 2018. Competition is heating up and IP issues are in the process of being settled.

Next earnings report for Q1/14 is due on 1st of May 2014.

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
2	... an the latest: Illumina sues Ariosa alleging infringement of NIPT patents.	dr_elis	-	4/26/2014
1	SQNM competitor Ariosa files for IPO: venturebeat.com Very risky, if SQNM preva	dr_elis	-	4/26/2014

Go to reply# or date (mm/dd/yy):